[
    [
        {
            "time": "2018-11-08",
            "original_text": "Merck's Gardasil Gets FDA Approval for Head and Neck Cancers",
            "features": {
                "keywords": [
                    "Merck",
                    "Gardasil",
                    "FDA",
                    "Approval",
                    "Head",
                    "Neck",
                    "Cancers"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Merck's Gardasil Gets FDA Approval for Head and Neck Cancers",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-06-13",
            "original_text": "Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020",
            "features": {
                "keywords": [
                    "Roche",
                    "Venclexta",
                    "Positive",
                    "Data",
                    "EHA",
                    "2020"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2017-08-31",
            "original_text": "FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region",
            "features": {
                "keywords": [
                    "FDA",
                    "Approves",
                    "JUVÉDERM",
                    "VOLUMA",
                    "XC",
                    "Enhancement",
                    "Chin",
                    "Region"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "cosmetics"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-10",
            "original_text": "AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Showcase",
                    "Studies",
                    "Virtual",
                    "2020",
                    "Annual",
                    "Scientific",
                    "Meeting",
                    "American",
                    "Headache",
                    "Society"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]